Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix
The management of cervical cancer specific to histology, stage, and setting has changed tremendously and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.
Category
  • Cervical Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy for Biliary Tract Cancers
The landscape of targeted therapy continues to rapidly evolve, and pharmacists play an integral role on the interprofessional health care team. It is important for pharmacists to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.
Category
  • Hepatobiliary Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Adult Acute Lymphoblastic Leukemia
Side effects of novel therapies may be severe. Cytokine release syndrome, neurotoxicity, and sinusoidal obstruction syndrome (SOS/VOD) are just some of the serious adverse effects that may occur. With the expanding roles of monoclonal antibodies and CAR-T therapies in acute lymphoblastic leukemia (ALL), pharmacists should be aware of their proper place in therapy and side effect management for patient safety.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer
Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer
With expanding treatment options, clinicians should understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. It is important for clinicians to stay up-to-date with the available treatment options to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Advances in the Management of Metastatic Breast Cancer with SABCS Updates
This activity covers the following presentations:Advances in the Management of HR-Positive Metastatic Breast Cancer with SABCS UpdatesAdvances in the Management of HER2-Positive Metastatic Breast Cancer with SABCS Updates
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Locoregional Management of Breast Cancer with SABCS Updates
This activity covers the following presentations:Updates to Radiation Therapy for DCIS and Invasive Breast Cancer with SABCS UpdatesSurgical Management of Invasive Breast Cancer with SABCS Updates
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Multigene and Biomarker Testing in Breast Cancer
This activity covers the following presentations:Biomarkers and Gene Panel Testing in Early-Stage Breast CancerNext-Generation Sequencing Testing in the Metastatic Setting
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation

Pages